Board of Directors
Beth Seidenberg, MD
Partner, Kleiner Perkins Caufield & Byers
Dr. Beth Seidenberg focuses on life science investing in digital health and biotech and works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health. Since joining Kleiner Perkins Caufield & Byers in 2005, Beth has incubated five companies and was the founding CEO of two. She serves on the board of directors of 5 Digital Health Companies: Auxogyn, Mango Health, RedBrick Health, Practice Fusion and Spruce Health and 9 Biotech Companies: 3-V Biosciences, ARMO Biosciences, ACIR Biosciences, Breathe Technologies, Flexus and True North, including 3 publicly traded companies: Atara Bio (ATRA), Epizyme (EPZM) and Tesaro (TSRO). Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc. Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals. Beth grew up in New York and received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.
Carl L. Gordon, PhD, CFA
Carl is a founding Partner and Co-Head of Global Private Equity at OrbiMed. Mr. Gordon is active in both private equity and small-capitalization public equity investments. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. Mr. Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a bachelors degree from Harvard College.
Peter Van Vlasselaer, PhD
Founder, President and Chief Executive Officer, ARMO BioSciences
Peter Van Vlasselaer, PhD has over 20 years of experience in the biotech industry and has founded and led several companies. In addition to founding ARMO, Peter was a founder of Arresto BioSciences and co-founder of TrueNorth and ACIR BioSciences. He currently serves on the boards of ARMO, TrueNorth, and Blade Therapeutics. Previously, Peter was President and CEO of iPierian, ARRESTO BioSciences and AVIDIA. Beforehand, he was member of the start-up teams of the publicly trading companies InterMune (ITMN) and Dendreon (DNDN), where he was Senior Vice President Technical Operations and Vice President of Drug Development, respectively. Peter was a post-doctoral fellow in the Division of Immunology and Rheumatology at Stanford University, CA and at the Laboratory of Human Immunology at DNAX Research Institute in Palo Alto, CA and obtained a bachelor's degree in Zoology and a PhD in Immunology from the Catholic University of Leuven, Belgium. He has authored several peer reviewed scientific publications and book chapters and he is an inventor on multiple patents.